Thinly traded micro cap Aptinyx (NASDAQ:APTX) is up 14% premarket on average volume in response to positive Phase 2 data on NMDA modulator NYX-2925 in 23 patients with fibromyalgia, a disorder characterized by widespread musculoskeletal pain.
The study met its primary objective demonstrating statistically significant effects on brain activity biomarkers associated with central pain processing. Significant reductions in pain scores were also reported.
Enrollment in a larger randomized trial will begin in H2. The primary endpoint will be patient-reported outcomes.
Subscribe for full text news in your inbox